Venture Capital News | Private Equity News
Venture Capital Firms List / Venture Capital & Private Equity Firms and Sources
Published since 1998, VCPro Database is the most reliable, up-to-date and affordable venture capital directory
VCPro Database 2022 25th Edition — a downloadable and searchable venture capital database with 6,800+ venture capital and private equity firms worldwide. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database is available in both Windows and macOS versions. It has been published since 1998.
Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders
Financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and Series A investors Longitude Capital, Medicxi and RxCapital
CHARLOTTESVILLE, Va., September 22, 2022-- Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. This financing will further support clinical advancement of lead candidate HU6, a first-in-class Controlled Metabolic Accelerator (CMA) designed to treat cardio-metabolic disease by addressing obesity, a primary driver of disease.
"We have an exceptional group of investors who share our vision for bringing a new class of treatments to patients with obesity and cardio-metabolic disease," said Allen Cunningham, President and CEO of Rivus Pharmaceuticals. "Following encouraging data from our Phase 2a clinical trial in patients with obesity, this financing enables us to advance development of HU6 and a pipeline of Controlled Metabolic Accelerators to address a range of cardio-metabolic conditions."
"RA Capital is excited to lead this round to provide patients a differentiated approach to more effectively treat obesity and cardio-metabolic disease," said Derek DiRocco, partner at RA Capital and new board director. "While there have been several recent clinical successes in the treatment of obesity, CMAs stand alone in their ability to demonstrate significant fat reduction while sparing muscle mass, a very desirable profile especially in patients with diabetic myopathy and sarcopenia."
Nearly half of American adults are living with cardio-metabolic diseases, conditions that adversely impact a person's health and quality of life. Obesity is a common driver of cardio-metabolic disease, yet weight loss via lifestyle modification remains challenging for many patients. Rivus' CMAs are designed to safely harness mitochondrial uncoupling, a natural process that regulates and dissipates energy, to selectively reduce fat throughout the body. While numerous approaches are being explored to reduce energy intake in obesity, CMAs are unique in their focus on increasing energy expenditure, thereby avoiding loss of skeletal muscle mass as seen with other therapeutics.
Earlier this year, Rivus released data from a Phase 2a metabolic study investigating lead candidate HU6 in obese participants. The study provided proof of concept validation that CMAs have the potential to treat not only obesity, but a range of cardio-metabolic diseases including heart failure with preserved ejection fraction (HFpEF), type 2 diabetes and Nonalcoholic fatty liver disease (NAFLD)/Nonalcoholic steatohepatitis (NASH).
Key findings of the 8-week study include:
• HU6 demonstrated significant reductions in liver, visceral, and total body fat while conserving skeletal muscle mass, all without changes in diet or exercise. Weight loss was amplified in patients with elevated HbA1c.
• Reductions in liver fat were 30%-40% across doses and will be further quantified in a longer duration Phase 2b obesity study.
• Patients treated with HU6 saw improvement in key cardiovascular and metabolic health indicators including glycemic control, glycated albumin and HbA1c, reduction in blood pressure and inflammatory markers.
• Both Phase 1 and 2a metabolic data showed that HU6 was well tolerated across all dose levels with no Serious Adverse Events (SAEs) or deaths reported.
Rivus recently initiated a Phase 2a study in obese participants with heart failure with preserved ejection fraction (HFpEF) and plans to initiate a Phase 2b study in obesity, including a subset of obese participants with type 2 diabetes in 2023.
About HU6 and CMAs
HU6 is a Controlled Metabolic Accelerator (CMA) that provides a novel, measured approach to activating mitochondrial uncoupling, a natural process in the body by which the body generates heat. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat and sugars throughout the body.
About Rivus Pharmaceuticals
Rivus Pharmaceuticals, Inc., a leader in mitochondrial biology, is dedicated to improving cardio-metabolic health by advancing a new class of medicines, Controlled Metabolic Accelerators (CMAs). Harnessing a natural metabolic process, CMAs target a significant risk factor for these diseases – obesity, the result of excess fat accumulation in the body. Rivus' first-in-class small molecule therapy, HU6, represents a tremendous opportunity to empower patients on their journey to better health when facing a broad range of conditions, including obesity, heart failure with preserved ejection fraction (HFpEF), type 2 diabetes, and Nonalcoholic fatty liver disease (NAFLD)/Nonalcoholic steatohepatitis (NASH). For more information, please visit www.rivuspharma.com.